Racura Oncology Ltd (ASX:RAC)

Racura Oncology Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Other Revenue	6.04	4.84	3.13	0.71	0.39
Revenue	6.04	4.84	3.13	0.71	0.39
Revenue Growth (YoY)	24.96%	54.29%	342.83%	82.71%	143.07%
Cost of Revenue	0.64	2.61	2.03	0.99	0.62
Gross Profit	5.41	2.22	1.11	-0.28	-0.23
Selling, General & Admin	3.28	3.79	3.04	4.33	3.34
Research & Development	5.9	10.98	7.6	5.83	2.2
Amortization of Goodwill & Intangibles	0.28	0.28	0.28	0.28	0.28
Other Operating Expenses	0.66	0.82	0.66	0.48	0.31
Operating Expenses	10.12	15.87	11.58	10.92	6.13
Operating Income	-4.72	-13.65	-10.48	-11.2	-6.36
Interest & Investment Income	-	-	0.59	0.05	0.02
Other Non Operating Income (Expenses)	-0.07	-0.17	-0.04	-0.05	-0.04
EBT Excluding Unusual Items	-4.79	-13.82	-9.92	-11.2	-6.38
Other Unusual Items	-	-	-	-	0.04
Pretax Income	-4.79	-13.82	-9.92	-11.2	-6.34
Net Income	-4.79	-13.82	-9.92	-11.2	-6.34
Net Income to Common	-4.79	-13.82	-9.92	-11.2	-6.34
Shares Outstanding (Basic)	172	165	161	153	131
Shares Outstanding (Diluted)	172	165	161	153	131
Shares Change (YoY)	4.81%	2.35%	4.83%	17.06%	22.86%
EPS (Basic)	-0.03	-0.08	-0.06	-0.07	-0.05
EPS (Diluted)	-0.03	-0.08	-0.06	-0.07	-0.05
Gross Margin	89.49%	45.96%	35.35%	-39.91%	-60.07%
Operating Margin	-78.03%	-282.30%	-334.22%	-1582.76%	-1641.48%
Profit Margin	-79.22%	-285.76%	-316.60%	-1582.63%	-1636.70%
EBITDA	-4.43	-13.37	-10.19	-10.92	-6.08
EBITDA Margin	-73.37%	-276.48%	-	-	-
D&A For EBITDA	0.28	0.28	0.28	0.28	0.28
EBIT	-4.72	-13.65	-10.48	-11.2	-6.36
EBIT Margin	-78.03%	-282.30%	-	-	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.